Tuesday, August 26, 2025

ViQi & Araceli partner on AI phenotypic cell assay profiling

Related stories

Databricks to Acquire Tecton, Bringing Real-Time Data Power to AI Agents

Databricks announced that it will acquire Tecton, a leading...

R Systems Acquires Novigo, Boosting Agentic-AI capabilities

R Systems International Limited, a global leader in digital...

NVIDIA Unveils Spectrum-XGS to Link Data Centers for AI

NVIDIA has introduced NVIDIA® Spectrum-XGS Ethernet, a next-generation networking...

Meta Strikes Licensing Deal with Midjourney to Advance AI Image and Video Tools

Meta has announced a strategic licensing partnership with Midjourney...

Fivetran & S3NS Partner to Secure Data Movement in Europe

Fivetran, a global leader in automated data movement, has...
spot_imgspot_img

ViQi and Araceli Biosciences collaborated to integrate ViQi’s AI-powered image analysis with Araceli’s high-throughput imaging platform.

ViQi, Inc. and Araceli Biosciences announced a dynamic collaboration to leverage ViQi’s revolutionary AI-driven image analysis technology with Araceli’s unmatched imaging innovations of their cutting-edge Araceli Endeavor® Ultra High Throughput – High Content Imaging Platform to advance AI-driven phenotypic profiling in high throughput (HTP) cell-based assays. This collaboration will both align efforts to bring novel imaging assays to market as well as transform how cutting-edge technology is showcased, celebrated, and embraced by the scientific community.

“This collaboration enables ViQi to further serve customers by offering a coordinated effort to not only meaningfully analyze terabytes of imaging data but to enable scientific labs to generate this large amount of data in the first place,” said Kathy Yeung, ViQi’s CEO. “Using AI-driven analysis has proven to be increasingly valuable. The Endeavor’s speed to generate a lot of high quality image data means ViQi’s predictive AI technology can draw out meaningful insights that wouldn’t otherwise be realized.”

Also Read: Clario & AWS Partner on GenAI for Clinical Data Analysis

Matt Beaudet, CEO of Araceli added “As biological datasets grow exponentially, the challenge isn’t just capturing more data—it’s making it usable in real time. At Araceli, we’re focused on enabling both speed and clarity, and we partner with innovators who push that boundary.

ViQi‘s platform is a standout—bringing structure, speed, and insight to complex phenotypic data. We’re excited to see what their customers can unlock with Endeavor fueling the front end.”

Source: PRweb

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img